Rekah Pharmaceutical Industry Ltd.

TASE:REKA 주식 보고서

시가총액: ₪163.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Rekah Pharmaceutical Industry 관리

관리 기준 확인 4/4

Rekah Pharmaceutical Industry's CEO는 Mordechai Elgrabli, Apr2015 에 임명되었습니다 의 임기는 9.25 년입니다. 총 연간 보상은 ₪ 1.01M, 100% 로 구성됩니다. 100% 급여 및 0% 보너스(회사 주식 및 옵션 포함). 는 ₪ 27.75M 가치에 해당하는 회사 주식의 15.32% 직접 소유합니다. 27.75M. 경영진과 이사회의 평균 재임 기간은 각각 8.2 년과 9.3 년입니다.

주요 정보

Mordechai Elgrabli

최고 경영자

₪1.0m

총 보상

CEO 급여 비율100.0%
CEO 임기9.5yrs
CEO 소유권15.3%
경영진 평균 재임 기간8.5yrs
이사회 평균 재임 기간9.5yrs

최근 관리 업데이트

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

CEO 보상 분석

Mordechai Elgrabli 의 보수는 Rekah Pharmaceutical Industry 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

₪7m

Mar 31 2024n/an/a

-₪6m

Dec 31 2023₪1m₪1m

-₪7m

Sep 30 2023n/an/a

-₪8m

Jun 30 2023n/an/a

-₪3m

Mar 31 2023n/an/a

-₪2m

Dec 31 2022₪845k₪845k

-₪2m

Sep 30 2022n/an/a

₪4m

Jun 30 2022n/an/a

₪3m

Mar 31 2022n/an/a

₪5m

Dec 31 2021₪830k₪830k

₪7m

Sep 30 2021n/an/a

₪5m

Jun 30 2021n/an/a

₪9m

Mar 31 2021n/an/a

₪10m

Dec 31 2020₪828k₪828k

₪11m

Sep 30 2020n/an/a

₪7m

Jun 30 2020n/an/a

₪5m

Mar 31 2020n/an/a

₪4m

Dec 31 2019₪832k₪832k

₪3m

Sep 30 2019n/an/a

₪6m

Jun 30 2019n/an/a

₪5m

Mar 31 2019n/an/a

₪7m

Dec 31 2018₪801k₪801k

₪8m

Sep 30 2018n/an/a

₪246k

Jun 30 2018n/an/a

-₪8m

Mar 31 2018n/an/a

-₪11m

Dec 31 2017₪795k₪795k

-₪21m

보상 대 시장: Mordechai 의 총 보상 ($USD 279.16K ) IL 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 535.50K ).

보상과 수익: Mordechai 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Mordechai Elgrabli (80 yo)

9.5yrs

테뉴어

₪1,013,000

보상

Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...


리더십 팀

이름위치테뉴어보상소유권
Mordechai Elgrabli
CEO & Director9.5yrs₪1.01m15.32%
₪ 25.1m
Georgette Elgrabli
Director of Industrial Division & Directorno data₪1.62m15.32%
₪ 25.1m
Jacob Elgrably
Chief Executive Officer of Ophir Shalpharm7.4yrs₪920.00k데이터 없음
Nir Sella
Chief Executive Officer - Fresh of Life Pharma Ltd.3yrs₪907.00k데이터 없음
Meir Melumad
Director of Operationsno data₪684.00k데이터 없음
Yuval Elgrabli
Deputy CEO & Director of Business Development13.6yrs데이터 없음데이터 없음
Yaakov Elgrabli
Chief Executive Officer of Ophir & Shalpharm Ltdno data₪705.00k0.026%
₪ 43.1k

8.5yrs

평균 재임 기간

67.5yo

평균 연령

경험이 풍부한 관리: REKA 의 관리팀은 노련하고 경험 (평균 재직 기간 8.1 년)입니다.


이사회 구성원

이름위치테뉴어보상소유권
Mordechai Elgrabli
CEO & Director31.2yrs₪1.01m15.32%
₪ 25.1m
Georgette Elgrabli
Director of Industrial Division & Director31.2yrs₪1.62m15.32%
₪ 25.1m
Ishay Davidi
Director9.5yrs데이터 없음데이터 없음
Avraham Bigger
Chairman9.5yrs₪400.00k데이터 없음
Orly Zilberman
Independent External Director9.5yrs데이터 없음데이터 없음
Arnon Zo-Haaretz
Independent External Director7.9yrs데이터 없음데이터 없음
Ehud Nissan
Independent External Director7.9yrs데이터 없음데이터 없음
Amir Widmann
Directorless than a year데이터 없음데이터 없음

9.5yrs

평균 재임 기간

67.5yo

평균 연령

경험이 풍부한 이사회: REKA 의 이사회경험(평균 재직 기간 9.2 년)으로 간주됩니다.